

Pharmacy Prior Approval Request for Evrysdi

Beneficiary Information			
1. Beneficiary Last Name: 2. First Name: 3. Beneficiary ID #: 4. Beneficiary Date of Birth: 5. Beneficiary General Street S			
3. Beneficiary ID #:	4. Beneficiary Date of Birth:	5. Bene	ficiary Gender:
Prescriber Information			
6. Prescribing Provider NPI #:			
	n - Name:		Ext
Drug Information			
8. Drug Name:	9. Strength:	10. Quantity Per	30 Days:
11. Length of Therapy (in days):	up to 30 Days 🗆 60 Days 🗆 90 Days 🗆] 120 Days □ 180 Days □ 36.	5 Days 🗆 Other
Clinical Information			
For initial authorization request	s, please answer questions 1-5		
1. Is the patient 2 months of age	or older? \square Yes \square No		
2. Does the beneficiary have a diagnosis of 5q-autosomal recessive spinal muscular atrophy (SMA)? \square Yes \square No			
3. Does the beneficiary have SMA	A phenotype 1, 2, 3? \square Yes \square No		
4. Will the beneficiary use Evryso	di concomitantly with nusinersen (Sp	inraza) or onasemnogene a	beparvovec-xioi
(Zolgensma)? ☐ Yes ☐ No			
5. Is this medication being prescr	ribed by or in consultation with a new	urologist? 🗆 Yes 🗆 No	
For reauthorization, please answ	wer questions 1-7		
7. Has the beneficiary had clinica ☐ Stability or improvement in scales: Hammersmith Infan (HFMSE), Children's Hospit	ed any treatment related adverse effally meaningful response to treatment net motor function/milestones, included the Neurologic Exam (HINE), Hammers all of Philadelphia Infant Test of Neurologic Exam (BSID-III), 6-14 development Third Ed. (BSID-III), 6-14 development Third Ed.	nt as demonstrated by at le luding but not limited to th smith Functional Motor Sca romuscular Disorders (CHO	ast 1 of the following: e following validated le Expanded P INTEND), Bayley
☐ Stability or improvement i	in respiratory function tests [e.g. for	ced vital capacity (FVC), etc	.]
☐ Reduction in exacerbation the preceding year/timefr	ns necessitating hospitalization and/crame	or antibiotic therapy for res	piratory infection in
☐ Stable or increased patien	it weight (for patients without a gast	rostomy tube)	
☐ Slowed rate of decline in t	the aforementioned measures		
Signature of Prescriber:	rescriber Signature Mandatory)	Date:	
(P	rescriber Signature Mandatory)		

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

Fax this form to: (833) 404-2393 Pharmacy PA Call Center: (833) 585-4309